Physician profile
Drake E Bellanger
NPI 1659302586
$2,718.75
in general payments reported to CMS, 2019-2025
12 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.00 · 2020: $37.50 · 2021: $523 · 2022: $325 · 2023: $235 · 2024: $593 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.08 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,784.22 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Lilly USA, LLC | $286.75 | 2024-2025 | Zepbound, Mounjaro |
| Ethicon US, LLC | $275.20 | 2019-2024 | Certus 140, Echelon Flex, Harmonic |
| Currax Pharmaceuticals LLC | $108.22 | 2022-2023 | Contrave |
| Kvk-Tech, INC. | $77.26 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $51.46 | 2025 | Zenpep |
| Dilon Technologies, INC. | $38.90 | 2025 | Hemoblast Bellows |
| Tactile Systems Technology INC | $24.16 | 2025 | Nimbl, Flexitouch Plus |
| Intra-Sana Laboratories | $21.34 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Teleflex LLC | $19.89 | 2025 | Titan Sgs Bailout Chuck |
| Endo Pharmaceuticals INC. | $19.49 | 2023 | Nascobal |
| Tela Bio, INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drake Bellanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.